Regen Biopharma, Inc. Watch

from 8-K 23 pages 10% Promissory Note

from 8-K 25 pages Securities Purchase Agreement

from 10-Q 1 page Promissory Note (“Note”) - 10% Simple Interest June 5, 2024

from 10-Q 1 page Promissory Note (“Note”) - 10% Simple Interest May 3, 2024

from 8-K 1 page Sublease Agreement

from 8-K 1 page 3) Sublessor and Subtenant Agree That Except as Otherwise Specifically Modified in This Amendment, the Sublease Agreement Has Not Been Modified, Supplemented, Amended, or Otherwise Changed in Any Way and the Sublease Agreement Remains in Full Force and Effect Between the Parties Hereto as Modified by This Amendment. to the Extent of Any Inconsistency Between the Terms and Conditions of the Sublease Agreement and the Terms and Conditions of This Amendment, the Terms and Conditions of This Amendment Shall Apply and Govern the Parties, Agreed to By: Bst Partners, Inc. Regen Biopharma,inc. By:/S/ David Koos By:/S/ David Koos Chairman and CEO Chairman and CEO 4/26/2024 4/26/2024

from 8-K 1 page Consultant’s Fee Agreement

from S-1 3 pages Via E-Mail: Lnfo@natco.com Nevada Agency and Transfer Company 50 West Liberty Street, Suite 880 Reno, NV 89501 Attn: Restricted Securities Department

from S-1 7 pages Material contract

from S-1 ~5 pages Convertible Promissory Note

from S-1 7 pages Material contract

from S-1 7 pages Material contract

from S-1 7 pages Material contract

from S-1 7 pages Material contract

from S-1 3 pages Agreement by and Between Kcl Therapeutics, Inc. and Oncology Pharma Inc

from S-1 3 pages Agreement by and Between Regen Biopharma, Inc. and Oncology Pharma Inc

from S-1 3 pages License Assignment and Consent Agreement

from S-1 3 pages Agreement by and Between Regen Biopharma, Inc. and Zander Therapeutics, Inc

from 8-K 4 pages Registration Rights Agreement

from 8-K 5 pages Common Stock Purchase Agreement